Cholelithiasis is associated with SIGNIFOR use. Perform gallbladder ultrasounds before and at 6- and 12- month intervals.
SIGNIFOR: THE FIRST APPROVED MEDICAL THERAPY TO BIND AND ACTIVATE SSTS IN PITUITARY ADENOMAS1,2
A KEY REGULATOR OF ACTH SECRETION IS sst5
Results are the mean±SEM of IC50 values expressed as nmol/l.
SIGNIFOR® (pasireotide) Injection, for subcutaneous use
SIGNIFOR is indicated for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative.
IMPORTANT SAFETY INFORMATION
Warnings and Precautions:
The most common adverse reactions (frequency ≥20% in either group) occurring in patients receiving SIGNIFOR in clinical trials were:
Please see full Prescribing Information.